Brookdale Senior Living (BKD) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
19 Feb, 2026Executive summary
Achieved a 19% increase in Adjusted EBITDA for 2025 to $458M, marking the fourth consecutive year of double-digit growth and surpassing guidance.
Fourth quarter 2025 weighted average occupancy reached 82.5%, the highest since Q1 2020, with a 310 bps year-over-year increase.
Adjusted Free Cash Flow turned positive for the first time since 2020, at $23M for 2025.
Portfolio optimization included lease terminations, asset sales, and streamlining to 517 communities by mid-2026.
Strategic priorities focused on operational excellence, real estate optimization, capital reinvestment, leverage reduction, and quality elevation.
Financial highlights
2025 Adjusted EBITDA was $458M, up 19% year-over-year, and full year resident fee revenue grew 2.4% to $3.04B.
RevPAR increased 5.7% year-over-year to $5,134; Q4 2025 RevPAR up 7.1% to $5,219.
Q4 2025 Adjusted EBITDA was $106M, up 7% year-over-year.
Adjusted Free Cash Flow for 2025 was $22.8M, first positive year since 2020.
Q4 2025 resident fees decreased 4% year-over-year to $714.5M, mainly due to community dispositions.
Outlook and guidance
2026 guidance: 8–9% RevPAR growth and Adjusted EBITDA of $502M–$516M.
Mid-teens Adjusted EBITDA growth expected through 2028, with leverage targeted below 6x by end of 2028.
Average occupancy is expected to exceed 83% in 2026, benefiting from favorable supply-demand dynamics.
Non-development CapEx projected at $175M–$195M for 2026, up from $170.7M in 2025.
Guidance includes $162M in G&A expense and $180M in annual cash facility operating lease payments.
Latest events from Brookdale Senior Living
- Operational focus, targeted CapEx, and market-driven M&A support growth amid strong demand.BKD
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Q2 saw 20% Adjusted EBITDA growth, higher occupancy, but a wider net loss on higher costs.BKD
Q2 20241 Feb 2026 - 2026 targets $502–$516M Adjusted EBITDA and 8–9% RevPAR growth, led by operational transformation.BKD
Investor Day 202630 Jan 2026 - Q3 2024 delivered 15% EBITDA growth, higher occupancy, and $610M in acquisitions pending.BKD
Q3 202415 Jan 2026 - Strategic acquisitions, strong occupancy, and HealthPlus expansion drive positive 2025 outlook.BKD
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Accelerating occupancy, strong cash flow, and innovation position for sustained growth.BKD
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - 2024 results beat guidance; 2025 targets 11%-15% EBITDA growth and positive cash flow.BKD
Q4 202415 Dec 2025 - Contested director election, performance-based pay, and auditor ratification headline the 2025 proxy.BKD
Proxy Filing1 Dec 2025 - Ortelius seeks to overhaul board leadership to address underperformance and drive value creation.BKD
Proxy Filing1 Dec 2025